Statin use and risk of Parkinson's disease: A meta-analysis

Behavioural Brain Research

Volumn 309, Issue , 2016, Pages 29-34

  Sheng, Zhiguo ^a   Jia, Xiaobo ^b   Kang, Meini ^c  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c Tianjin United Family Hospital   (China)

Author keywords

Meta analysis; Parkinson's disease; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; ASIAN; CASE CONTROL STUDY; COHORT ANALYSIS; HUMAN; OBSERVATIONAL STUDY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SELF REPORT; SMOKING; SYSTEMATIC REVIEW; META ANALYSIS; RISK;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PARKINSON DISEASE; RISK;

EID: 84966708034     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.04.046     Document Type: Article

References (30)

1. Forno L.S. Neuropathology of parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
2. Schapira A.H., Gu M., Taanman J.W., et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 1998, 44:S89-S98.
3. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S26-S36.
4. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection. Lancet Neurol. 2009, 8:382-397.
5. Mogi M., Kondo T., Mizuno Y., Nagatsu T. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci. Lett. 2007, 414:94-97.
6. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26:S1-S58.
7. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
8. Devaraj S., Chan E., Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J. Clin. Endocrinol. Metab. 2006, 91:4489-4496.
9. Wood W.G., Eckert G.P., Igbavboa U., Muller W.E. Statins and neuroprotection: a prescription to move the field forward. Ann. N. Y. Acad. Sci. 2010, 1199:69-76.
10. Wang Q., Yan J., Chen X., et al. Statins: multiple neuroprotective mechanisms in eurodegenerative diseases. Exp. Neurol. 2011, 230:27-34.
11. Selley M.L. Simvastatin prevents l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 2005, 1037:1-6.
12. Huang X., Abbott R.D., Petrovitch H., Mailman R.B., Ross G.W. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov. Disord. 2008, 23:1013-1018.
13. Miyake Y., Tanaka K., Fukushima W., et al. Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J. Neurol. Sci. 2010, 293:82-86.
14. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
15. Ottawa Hospital Research Institute The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 2.05.12).
16. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
17. Huang X., Chen H., Miller W.C., et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov. Disord. 2007, 22(3):377-381.
18. Wahner A.D., Bronstein J.M., Bordelon Y.M., et al. Statin use and the risk of Parkinson disease. Neurology 2008, 70(16 Part 2):1418-1422.
19. Samii A., Carleton B.C., Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J. Clin. Neurosci. 2008, 15(11):1272-1273.
20. Ritz B., Manthripragada A.D., Qian L., et al. Statin use and Parkinson's disease in Denmark. Mov. Disord. 2010, 25(9):1210-1216.
21. Becker C., Jick S.S., Meier C.R. Use of statins and the risk of Parkinson's disease. Drug Saf. 2008, 31(5):399-407.
22. de Lau L.M.L., Stricker B.H.C., Breteler M. Serum cholesterol: use of lipid-lowering drugs, and risk of Parkinson disease. Mov. Disord. 2007, 22(13). 1985-1985.
23. Wolozin B., Wang S.W., Li N.C., et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007, 5(1):20.
24. Gao X., Simon K.C., Schwarzschild M.A., et al. Prospective study of statin use and risk of Parkinson disease. Arch. Neurol. 2012, 69(3):380-384.
25. Lee Y.C., Lin C.H., Wu R.M., et al. Discontinuation of statin therapy associates with Parkinson disease a population-based study. Neurology 2013, 81(5):410-416.
26. Friedman B., Lahad A., Dresner Y., et al. Long-term statin use and the risk of Parkinson's disease. Am. J. Managed Care 2013, 19(8):626-632.
27. Huang X., Alonso A., Guo X., et al. Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. Mov. Disord. 2015, 30(4):552-559.
28. Undela K., Gudala K., Malla S., et al. Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. J. Neurol. 2013, 260(1):158-165.
29. E. Lamperti, R. Musanti, N. Rocca, et al., Decreased concentration of low-density-lipoprotein cholesterol in patients with parkinsons-disease[C]//Clinical research. 6900 Grove Rd, Thorofare, NJ 08086 USA: Slack Inc (1991), 39(2), A401-A401.
30. Musanti R., Parati E., Lamperti E., et al. Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease. Biochem. Med. Metab. Biol. 1993, 49(2):133-142.